Read for the Registry
News & Events
GH CEA Registry
Measuring “fearonomic effects” in valuing therapies: An application to COVID-19 in China
July 27, 2020
Value in Health
Ma S, Kim DD, Cohen JT, Neumann PJ. "Measuring “fearonomic effects” in valuing therapies: An application to COVID-19 in China," Value in Health (in press).
Perspective and costing in cost-effectiveness analysis, 1974–2018
Crisis into opportunity: Can COVID-19 help set a path to improved health care efficiency?
Patient characteristics and treatment patterns among Medicare beneficiaries initiating PCSK9 inhibitor therapy
View All Publications